Risk-adapted use of intravesical immunotherapy

被引：12

作者：

Braasch, Matthew R. ^{[1
]}

Boehle, Andreas ^{[2
]}

O'Donnell, Michael A. ^{[1
]}

机构：

[1] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA

[2] Helios Agnes Karll Hosp, Bad Schwartau, Germany

来源：

BJU INTERNATIONAL | 2008年 / 102卷 / 09期

关键词：

bladder cancer; immunotherapy; survival analysis;

D O I：

10.1111/j.1464-410X.2008.07968.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

[No abstract available]

引用

收藏

页码：1254 / 1264

页数：11

相关论文

共 89 条

[1]

Intravesical bacillus Calmette-Guerin therapy:: experience with a reduced dwell-time in patients with pronounced side-effects [J].

Andius, P ;

Fehrling, M ;

Holmäng, S .

BJU INTERNATIONAL, 2005, 96 (09) :1290-1293

[2]

Modified induction course: A solution to side-effects? [J].

Bassi, P ;

Spinadin, R ;

Carando, R ;

Balta, G ;

Pagano, F .

EUROPEAN UROLOGY, 2000, 37 :31-32

[3]

Superficial bladder cancer:: The role of interferon-α [J].

Belldegrun, AS ;

Franklin, JR ;

O'Donnell, MA ;

Gomella, LG ;

Klein, E ;

Neri, R ;

Nseyo, UO ;

Ratliff, TL ;

Williams, RD .

JOURNAL OF UROLOGY, 1998, 159 (06) :1793-1801

[4]

Böhle A, 2004, UROLOGY, V63, P682, DOI 10.1016/j.urology.2003.11.049

[5]

Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer:: A formal meta-analysis of comparative studies on recurrence and toxicity [J].

Böhle, A ;

Jocham, D ;

Bock, PR .

JOURNAL OF UROLOGY, 2003, 169 (01) :90-95

[6]

Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response [J].

Bui, TT ;

Schellhammer, PF .

UROLOGY, 1997, 49 (05) :687-690

[7]

The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: Results of a randomized, prospective, double-blind, placebo controlled, multicenter study [J].

Colombel, Marc ;

Saint, Fabien ;

Chopin, Dominique ;

Malavaud, Bernard ;

Nicolas, Ludovic ;

Rischmann, Pascal .

JOURNAL OF UROLOGY, 2006, 176 (03) :935-939

[8]

Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder [J].

Dalbagni, G ;

Russo, P ;

Bochner, B ;

Ben-Porat, L ;

Sheinfeld, J ;

Sogani, P ;

Donat, MS ;

Herr, HW ;

Bajorin, D .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2729-2734

[9]

Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value [J].

DeReijke, TM ;

DeBoer, EC ;

Kurth, KH ;

Schamhart, DHJ .

JOURNAL OF UROLOGY, 1996, 155 (02) :477-482

[10]

*EUR ORG RES TREAT, EORTC RISK TABL PRED

← 1 2 3 4 5 6 7 8 9 →